MedTrace Logo

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

NCT02658214 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-08-20

No results posted yet for this study

Summary

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

Conditions

  • Small Cell Lung Carcinoma
  • Carcinoma, Squamous Cell of Head and Neck
  • Stomach Neoplasms
  • Triple Negative Breast Neoplasms
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Esophagogastric Junction Neoplasms
  • Carcinoma, Pancreatic Ductal
  • Esophageal Squamous Cell Carcinoma

Interventions

DRUG

paclitaxel + carboplatin

IV infusion

DRUG

carboplatin + etoposide

IV infusion

DRUG

gemcitabine + carboplatin

IV infusion

DRUG

nab-paclitaxel (paclitaxel-albumin) + carboplatin

IV infusion

DRUG

oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)

IV infusion and bolus administration

BIOLOGICAL

durvalumab

IV infusion

BIOLOGICAL

tremelimumab

IV infusion

DRUG

nab-paclitaxel (paclitaxel-albumin) + gemcitabine

IV infusion

DRUG

cisplatin + 5-fluorouracil (5FU)

IV infusion

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-28
Primary Completion
2019-11-14
Completion
2019-11-14
FDA Drug
Yes

Countries

  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658214 on ClinicalTrials.gov